Sihuan Pharmaceutical Holdings Group Ltd - Secured rights to distribute a ‘popular’ CV drug, Edaravone

• Sihuan Pharmaceutical Holdings Group Ltd (“Sihuan”), a leading manufacturer of cardiocerebral vascular (CV) drugs in China, has been awarded the rights to sell and distribute the already popular drug Edaravone in the PRC.

• Sihuan’s wholly-owned Shenzhen Sihuan Pharmaceutical Co., Ltd. will pay RMB 3 million for the right to distribute the drug for 5 years commencing from 8 October 2008, the date of successful registration with China’s State Food and Drug Administration.

• Edaravone is an active ingredient which protects the brain by quickly eliminating excessive free radicals which are highly reactive molecules occurring in the human body, particularly after a stroke, and stabilizes the patient’s condition.

• The drug is also one of the most effective neuro-protective agents and is in fact, the only neuro-protective agent recommended by the Japan Stroke Therapeutic Guide (2004) for the prevention of brain-cell damage arising from strokes.

• Sihuan manufactures drugs at its own production facilities but also engages third-party contract manufacturers. In addition, it is the exclusive distributor of several drugs for an unrelated pharmaceutical company.

The above is reproduced from Westcomb Research